Anthony B Pinkerton

9PUBLICATIONS
32CO-AUTHORS
Molecular targetsAutonomic nervous systemPharmacogenomicsClinical pharmacology and therapeuticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 15, 2026
Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers.

|Nov 07, 2024
Enhancing transcription-replication conflict targets ecDNA-positive cancers.

Jun Tang, Natasha E Weiser, Guiping Wang

|Mar 14, 2023
Neurotensin Receptor Allosterism Revealed in Complex with a Biased Allosteric Modulator.

Brian E Krumm, Jeffrey F DiBerto, Reid H J Olsen

|Mar 10, 2022
An Optimized Dihydrodibenzothiazepine Lead Compound (SBI-0797750) as a Potent and Selective Inhibitor of Plasmodium falciparum and P. vivax Glucose 6-Phosphate Dehydrogenase 6-Phosphogluconolactonase.

Isabell Berneburg, Satyamaheshwar Peddibhotla, Kim C Heimsch

|Apr 29, 2021
Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.

Stephanie M Stanford, Michael A Diaz, Robert J Ardecky

|Jan 08, 2021
Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth.

Shinji Iizuka, Manuela Quintavalle, Jose C Navarro

Pageof 2

Frequent Collaborators

2 joint publications

Lauren M Slosky

1 joint publications

Shira G Ziegler

1 joint publications

Elena Gallo MacFarlane

1 joint publications

Ryan C Riddle